study of Liu et al. [2] did not seem to agree with the data reported in Liu et al.'s original publication [2] . The numbers reported by Liu et al. [2] for the TT, CT and CC genotypes were 88, 175 and 102 among the cases and 185, 313 and 133 among the controls, respectively (shown in Table 2 of Liu et al.'s original publication) [2] . Interestingly, after carefully examining the data reported by Liu et al. [1] , the numbers for TT, CT and CC were 185, 313 and 133 among the cases and 88, 175 and 102 among the controls, respectively (shown in Table 1 of Liu et al.'s paper) [1] . Second, the data reported by Liu et al. [1] for the study reported by Akisik et al. [3] did not seem to agree with the data from Akisik et al.'s study [3] in their original publication. The numbers reported by Akisik et al. [3] for the TT and CC genotypes were 45 and 18 among the cases and 33 and 21 among the controls, respectively (shown in Table 2 of Akisik et al.'s original paper). Interestingly, after carefully examining the data reported by Liu et al. [1] , the numbers for TT and CC were 18 and 45 among the cases and 21 and 33 among the controls, respectively (shown in Table 1 of Liu et al.'s paper) [1] . Thus, the above discrepancies imply that the association between the IL-1b -31T[C polymorphism and the risk of breast cancer is not entirely credible. The association between the IL-1b -31T[C polymorphism and breast cancer risk requires clarification. We reassessed this association by conducting an updated meta-analysis based on 1277 breast cancer cases and 1431 controls that could provide comprehensive evidence for the association of the IL-1b -31T[C polymorphism with breast cancer risk. A cumulative meta-analysis that accumulated the data according to the year of publication was simultaneously conducted.
The general information about the eligible studies is listed in Table 1 . The summary ORs of the association between the IL-1b -31T[C polymorphism and breast cancer risk are listed in Table 2 . Overall, we did not observe any significant association between the IL-1b -31T[C polymorphism and breast cancer risk. The summary ORs were 1.13 (95 % CI 0.92-1.40) for CC versus TT, 0.97 (95 % CI 0.91-1.04) for CT versus TT, 1.01 (95 % CI 0.96-1.05) for CT ? CC versus TT and 1.06 (95 % CI 0.96-1.16) for the C allele versus the T allele, respectively (Fig. 1a-d) . Similar results were found in our cumulative meta-analysis, which indicated that there was not any significant association between the IL-1b -31T[C polymorphism and breast cancer risk. The cumulative ORs were 1.24 (95 % CI 0.85-1.82) for CC versus TT, 0.92 (95 % CI 0.77-1.10) for CT versus TT, 1.02 (95 % CI 0.86-1.21) for CT ? CC versus TT and 1.11 (95 % CI 0.92-1.33) for the C allele versus the T allele, respectively. These findings increased the reliability of our results to certain extent. The results of Begg's test and Egger's test revealed no evidence of publication bias in this study (Table 2) .
In summary, the results reported by Liu et al. [1] should be expounded with caution. To reach a definitive conclusion, additional well-designed studies with larger sample sizes are still required to evaluate the association between the IL-1b -31T[C polymorphism and breast cancer risk. We hope that our remarks will contribute to more accurate elaboration and substantiation of the results reported by Liu et al. [1] . 
